Lavender Sky Health Semaglutide: Clinician-Led Practice Model

Does a clinician-led appointment change what the medicine is?

No. An appointment describes how care is delivered; FDA's treatment of a compounded product depends on how it is compounded and prescribed, as the next section sets out [1][2].

What FDA describes for a compounded prescription

FDA says a compounded drug product must be compounded for an individual patient based on receipt of a prescription [2]. FDA treats a product as essentially a copy of a commercially available drug when its active ingredient is present in a strength that is the same, similar or easily substitutable and the product is given by the same route as the commercial drug [2]. FDA says it does not intend to take action against a compounder for such a copy when the compounder fills four or fewer prescriptions of that product in a calendar month, and describes an exception where a prescriber determines and documents a change that produces a significant difference for an identified patient [2].

Adding an ingredient does not automatically move a product out of the copy category. FDA gives the example of semaglutide combined with vitamin B12 and says it may still be essentially a copy when the products are given the same way and the amounts of semaglutide and vitamin B12 are within 10% of the strengths of the commercial products [2].

What the approved labels cover

Wegovy injection is approved for weight reduction in adults and children 12 and older with obesity, cardiovascular risk reduction in adults with established cardiovascular disease plus obesity or overweight, and noncirrhotic MASH with fibrosis stages F2 to F3; Wegovy tablets are for adults only [3]. Ozempic is approved for adults with type 2 diabetes (glycemic control, cardiovascular risk reduction and kidney outcomes) and has no weight-loss indication [4].

The Wegovy, Ozempic and Rybelsus/Ozempic tablet labels carry a boxed warning about thyroid C-cell tumors seen in rodents, and semaglutide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [3][4][5]. In pooled trials of Wegovy 2.4 mg injection (2,116 adults on Wegovy, 1,261 on placebo, up to 68 weeks), nausea occurred in 44% versus 16%, vomiting in 24% versus 6% and constipation in 24% versus 11%, and 6.8% versus 3.2% stopped treatment because of adverse reactions [3]. Those figures describe the approved product, not compounded versions.

What FDA has reported about compounded semaglutide

As of 31 May 2026 FDA had received 990 adverse event reports for compounded semaglutide and says this likely undercounts [1]. FDA reports dosing errors with compounded injectable semaglutide, including patients measuring the wrong dose and clinicians miscalculating [1]. For multi-dose vials, FDA recommends discarding the vial 28 days after first use even if medicine remains, and using a new sterile needle and syringe for every dose [1].

HealthRX.com offers compounded semaglutide by prescription.